Case Study: Dopamine D 3 Receptor Anthagonists Chapter 3 – Molecular Modeling 1.

Slides:



Advertisements
Similar presentations
3D Molecular Structures C371 Fall Morgan Algorithm (Leach & Gillet, p. 8)
Advertisements

Jürgen Sühnel Institute of Molecular Biotechnology, Jena Centre for Bioinformatics Jena / Germany Supplementary Material:
Computational Drug Design Apr 2010 Postgrad course on Comp Chem Noel M. O’Boyle.
6th lecture Modern Methods in Drug Discovery WS07/08 1 More QSAR Problems: Which descriptors to use How to test/validate QSAR equations (continued from.
1 © Patrick An Introduction to Medicinal Chemistry 3/e Chapter 10 DRUG DESIGN: OPTIMIZING TARGET INTERACTIONS Part 5: Section
1 PharmID: A New Algorithm for Pharmacophore Identification Stan Young Jun Feng and Ashish Sanil NISSMPDM 3 June 2005.
Molecular Docking G. Schaftenaar Docking Challenge Identification of the ligand’s correct binding geometry in the binding site ( Binding Mode ) Observation:
Two Examples of Docking Algorithms With thanks to Maria Teresa Gil Lucientes.
M. Wagener 3D Database Searching and Scaffold Hopping Markus Wagener NV Organon.
Quantative Structure- Activity Relationships. Why QSAR? The number of compounds required for synthesis in order to place 10 different groups in 4 positions.
Quantitative Structure-Activity Relationships (QSAR) Comparative Molecular Field Analysis (CoMFA) Gijs Schaftenaar.
FLEX* - REVIEW.
Bioinformatics IV Quantitative Structure-Activity Relationships (QSAR) and Comparative Molecular Field Analysis (CoMFA) Martin Ott.
BL5203: Molecular Recognition & Interaction Lecture 5: Drug Design Methods Ligand-Protein Docking (Part I) Prof. Chen Yu Zong Tel:
Pharmacophore-based Molecular Docking Bert E. Thomas, Diane Joseph- McCarthy, Juan C.Avarez.
Molecular Docking Using GOLD Tommi Suvitaival Seppo Virtanen S Basics for Biosystems of the Cell Fall 2006.
Structural biology and drug design: An overview Olivier Taboureau Assitant professor Chemoinformatics group-CBS-DTU
RAPID: Randomized Pharmacophore Identification for Drug Design PW Finn, LE Kavraki, JC Latombe, R Motwani, C Shelton, S Venkatasubramanian, A Yao Presented.
Virtual Screening protein-ligand interactions, inhibitors, SBDD –kinetics, competitive, slow, aggregators –H-bonding, halogens, co-factors, metal ions.
Drug Design Process Discovery Phase. Tripos Software n SYBYL & its modules SYBYL, Concord, MOLCAD, SiteId, Advanced Computation, GASP, DISCOtech, HQSAR,
Computational Techniques in Support of Drug Discovery October 2, 2002 Jeffrey Wolbach, Ph. D.
Molecular Descriptors
Molecular Docking S. Shahriar Arab. Overview of the lecture Introduction to molecular docking: Definition Types Some techniques Programs “Protein-Protein.
Drug Design Optimizing Target Interactions
ClusPro: an automated docking and discrimination method for the prediction of protein complexes Stephen R. Comeau, David W.Gatchell, Sandor Vajda, and.
Molecular Modeling: Conformational Molecular Field Analysis (CoMFA)
DE NOVO DESIGN OF A THYMIDYLATE KINASE INHIBITOR.
Designing a Tri-Peptide based HIV-1 protease inhibitor Presented by, Sushil Kumar Singh IBAB,Bangalore Submitted to Dr. Indira Ghosh AstraZeneca India.
1. Chemometrices:  Signal processing  Classification & pattern reccognation  Experimental design  Multivariative calibration  Quantitative Structure.
Know More Before You Score: An Analysis of Structure-Based Virtual Screening Protocols ä Structure-Based Virtual Screening (SBVS) is a proven technique.
Modern Tools of Drug Discovery
3D- QSAR. QSAR A QSAR is a mathematical relationship between a biological activity of a molecular system and its physicochemical parameters. QSAR attempts.
Protein Folding and Modeling Carol K. Hall Chemical and Biomolecular Engineering North Carolina State University.
Altman et al. JACS 2008, Presented By Swati Jain.
1 © Patrick An Introduction to Medicinal Chemistry 3/e Chapter 10 DRUG DESIGN: OPTIMIZING TARGET INTERACTIONS Part 2: Section 10.2.
Virtual Screening C371 Fall INTRODUCTION Virtual screening – Computational or in silico analog of biological screening –Score, rank, and/or filter.
Bioinformatics MEDC601 Lecture by Brad Windle Ph# Office: Massey Cancer Center, Goodwin Labs Room 319 Web site for lecture:
Hierarchical Database Screenings for HIV-1 Reverse Transcriptase Using a Pharmacophore Model, Rigid Docking, Solvation Docking, and MM-PB/SA Junmei Wang,
Pharmacophores Chapter 13 Part 2.
Selecting Diverse Sets of Compounds C371 Fall 2004.
Computer-aided drug discovery (CADD)/design methods have played a major role in the development of therapeutically important small molecules for several.
R L R L L L R R L L R R L L water DOCKING SIMULATIONS.
Molecular Classification of Cancer Class Discovery and Class Prediction by Gene Expression Monitoring.
Time-Efficient Flexible Superposition of Medium-sized Molecules Presented by Tamar Sharir (Lemmen & Lengauer)
FlexWeb Nassim Sohaee. FlexWeb 2 Proteins The ability of proteins to change their conformation is important to their function as biological machines.
Surflex: Fully Automatic Flexible Molecular Docking Using a Molecular Similarity-Based Search Engine Ajay N. Jain UCSF Cancer Research Institute and Comprehensive.
How NMR is Used for the Study of Biomacromolecules Analytical biochemistry Comparative analysis Interactions between biomolecules Structure determination.
CoMFA Study of Piperidine Analogues of Cocaine at the Dopamine Transporter: Exploring the Binding Mode of the 3  -Substituent of the Piperidine Ring Using.
Molecular mechanics Classical physics, treats atoms as spheres Calculations are rapid, even for large molecules Useful for studying conformations Cannot.
Elon Yariv Graduate student in Prof. Nir Ben-Tal’s lab Department of Biochemistry and Molecular Biology, Tel Aviv University.
Molecular Modeling in Drug Discovery: an Overview
Julia Salas CS379a Aim of the Study To determine distinguishing features of orally administered drugs –Physical and structural features probed.
HP-SEE In the search of the HDAC-1 inhibitors. The preliminary results of ligand based virtual screening Ilija N. Cvijetić, Ivan O. Juranić,
SMA5422: Special Topics in Biotechnology Lecture 11: Computer aided drug design: QSAR approach. SMA5422: Special Topics in Biotechnology Lecture 11: Computer.
Page 1 Computer-aided Drug Design —Profacgen. Page 2 The most fundamental goal in the drug design process is to determine whether a given compound will.
Simplified picture of the principles used for multiple copy simultaneous search (MCSS) and for computational combinatorial ligand design (CCLD). Simplified.
Computational design of protein function
APPLICATIONS OF BIOINFORMATICS IN DRUG DISCOVERY
Ligand-Based Structural Hypotheses for Virtual Screening
Computer-aided Drug Design
Virtual Screening.
Current Status at BioChemtek
Ligand Docking to MHC Class I Molecules
Advanced Higher Chemistry Unit 3(e)
DRUG DESIGN: OPTIMIZING TARGET INTERACTIONS
Patrick: An Introduction to Medicinal Chemistry 6e
Mr.Halavath Ramesh 16-MCH-001 Dept. of Chemistry Loyola College University of Madras-Chennai.
Mr.Halavath Ramesh 16-MCH-001 Dept. of Chemistry Loyola College University of Madras-Chennai.
Mr.Halavath Ramesh 16-MCH-001 Dept. of Chemistry Loyola College University of Madras-Chennai.
Mr.Halavath Ramesh 16-MCH-001 Dept. of Chemistry Loyola College University of Madras-Chennai.
Presentation transcript:

Case Study: Dopamine D 3 Receptor Anthagonists Chapter 3 – Molecular Modeling 1

Today’s lecture 2 Dopamine D 3 Receptor Anthagonists Building a pharmacophore model 3D QSAR analysis

Dopamine Receptor 3 5 different subtypes: D 1, D 2, D 3, D 4, D 5 Defects is related to several diseases Parkinson’s disease, schizophrenia etc. Medical treatment Limited by side effects from drugs binding to various subreceptors Need selectivity!

Building a pharmacophore model 4 5 ligands (D 3 receptor antagonists) High affinity Known steric and electrostatic information Structure: Highly potent

Building a pharmacophore model 5 Strategy Decompose molecule into fragments Molecular allignment using FlexS One treated flexible One treated rigid

Building a pharmacophore model 6 Rigid part SYBYL: Simulated annealing Low T conformation Two clusters (conformation family) rigid

Building a pharmacophore model 7 Flexible part: Fit onto rigid part FlexS flexible

Building a pharmacophore model 8 The spacer Generally flexible Examined in detail: quite rigid overlap

Building a pharmacophore model 9 Simulated annealing on bicyclic ring system 3 conformations

Building a pharmacophore model 10 Aromatic/Amidic residue Assumed planar Include this restriction in previous examination planar

Building a pharmacophore model 11 Systematic search 10 degree increment Tripos force field → 992 conformations

Building a pharmacophore model 12 Compound 1 fitted on all 992 conformations with FlexS Highest rated = binding conformation of these fragments Compound 1

Building a pharmacophore model 13 Now we have the conformation of all fragments Recombine fragments Pharmacophore model!

Building a pharmacophore model 14 Molecular interaction fields with GRID C=O N-H ST-127 ST-84 ST-205 ST-86 H-bond acceptor Basic nitrogen

Building a pharmacophore model 15 ST-127 ST-84 ST-205 ST-86

Building a pharmacophore model 16

Building a pharmacophore model 17

3D QSAR Analysis 18 With a pharmacophore model Arrange potent molecules or fragments in their bioactive conformation Guideline for designing next- gen. enhanced compounds

3D QSAR Analysis D 3 antagonists Fitted to the pharmacophoric conformation (model) Superimposed onto each other (FlexS) Refined with SYBYL (steepest decent)

3D QSAR Analysis 20 Calculate GRID interaction fields for all 40 ligands Now with alot of probes probe-ligand interactions per compound! 14580: Too many variables! Will introduce noise

3D QSAR Analysis 21 To overcome the problem Filter out variables with only few values Filter out variables with low change (<10 -7 kcal/mol) If they all lie in a small interval they can be disregarded

3D QSAR Analysis 22 Next: Set up a PLS model (Partial Least Square) It can handle a statistical model with more energy values than compounds The energy values are correlated with each other Many of them are not important for the biological activity We can use a few different algorithms in the problem GOLPE to reduce the number of variables D-optimal (good >1000 variables) Fractional Factorial Design (FFD)

3D QSAR Analysis 23 Each time: Cross validate with Leave One Out (LOO) Make a model with all the compounds except one Predict its activity Do it with all compounds

3D QSAR Analysis 24 A Fractional Factorial Design (FFD) method determines the predictivity of each variable Each variable is classified as either Helpful for predictivity Destructive for predictivity Uncertain Only helpful variables are included in the PLS model Good to use after D-optimal has reduced the variables to a few thousand

3D QSAR Analysis 25 High cross validation value

3D QSAR Analysis 26 LOO cross validation in final model

3D QSAR Analysis 27 Validation of the 3D QSAR method Many variables were treated Chance correlation? Test with scrample set Randomly assign the binding affinities of the ligands Generate PLS model and reduce variables as before Cross validate with LOO

3D QSAR Analysis 28 Prediction of External ligands Try with some different type of structures that also shows reasonable binding activity towards the receptor Lies within ± 0.5 SDEP = 0.57